AstraZeneca enters a historically powerful seasonal window in early February – just as new clinical trial results and analyst forecasts signal renewed investor interest.

Real income rose slightly, but real spending rose substantially.

Today’s price action in Bitcoin and Ethereum confirms something important: both markets have rolled over, and momentum is shifting back to the downside.

It’s time for investors to rethink what safety really means.

The 25Q4 Y/Y blended earnings growth estimate is 63.3%. If the energy sector is excluded, the growth rate for the index is 70.9%.

Global equities ex-US are ahead 4.2% year to date — that’s a solid lead over US stocks, which are still trailing the rest of the world via a thin 0.5% increase.